# Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats

**Authors:** Paola Andrea Caro Aponte, Edison Huertas Montoya, Italo O. Mazali, Alessandra Sussulini, Benedito Barraviera, Rui Seabra Ferreira, Luciana Politti Cartarozzi, Alexandre Leite Rodrigues de Oliveira

PMC · DOI: 10.1111/jnc.70364 · 2026-01-29

## TL;DR

This study explores combining DMT and a surgical technique to protect neurons after spinal injuries in rats, showing promising results.

## Contribution

The novel combinatorial therapy of DMT and VRR is shown to enhance neuroprotection after spinal root avulsion.

## Key findings

- DMT at 1 mg/kg significantly enhanced motoneuron survival and reduced glial reactivity.
- Combining DMT with VRR further improved synaptic preservation and upregulated neurotrophic factors like GDNF.
- The combined therapy showed synergistic effects in protecting neurons after spinal injuries.

## Abstract

Currently, no effective treatment exists for injuries at the interface between the CNS/PNS, largely due to their complex pathophysiology and the limited efficacy of single‐target therapies. To address this challenge, we investigated a novel combinatorial therapeutic strategy integrating surgical VRR with fibrin sealant biopolymer (FSB) and DMT in a rat model of ventral root avulsion VRA. DMT was extracted from Mimosa tenuiflora roots and structurally characterized using standard analytical methods. Adult female Lewis rats underwent unilateral L4‐L6 VRA and received daily DMT treatment (1, 2.5, or 5 mg/kg; i.p) for 2 weeks to determine the optimal therapeutic dose. Subsequently, the identified optimal DMT dose was combined with VRR, and animals were evaluated 2 weeks post‐injury. Outcome measures encompassed quantitative assessments of neuronal survival, glial reactivity, synaptic preservation, and differential gene expression of neurotrophic factors (GDNF, FGF‐2, VGF‐A) and anti‐apoptotic genes (Bcl‐2, Bcl‐XL). Extracted DMT met all structural and analytical criteria for experimental use. Proximal axotomy led to substantial MN loss (78%), accompanied by pronounced glial reactivity and synaptic detachment. DMT at 1 mg/kg yielded the strongest neuroprotective profile, significantly enhancing MN survival, reducing glial reactivity, and preserving pre‐synaptic boutons. Notably, these effects were further potentiated when DMT treatment was combined with VRR. Moreover, the combined VRR + DMT therapy significantly upregulated GDNF expression, indicating a synergistic effect on neurotrophic support. Overall, our findings suggest that DMT is a promising neuroprotective agent for treating MN degeneration following CNS/PNS interface injuries, particularly when integrated into a combinatorial therapeutic strategy.

The ventral root avulsion (VRA) model provides an excellent experimental paradigm for studying injuries at the Central/Peripheral Nervous Systems (CNS/PNS) interface. By physically disconnecting motoneurons (MNs) from the spinal cord surface, VRA induces profound cellular, molecular, and functional deficits with limited spontaneous recovery. Given the complex pathophysiology underlying this injury, combined therapeutic strategies targeting multiple mechanisms simultaneously hold considerable promise. Here, we hypothesized that N, N dimethyltryptamine (DMT) and ventral root reimplantation (VRR) administered either as monotherapies but especially in combination could ameliorate degenerative changes and improve outcomes following VRA.

## Linked entities

- **Genes:** GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668], FGF2 (fibroblast growth factor 2) [NCBI Gene 2247], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], Bcl2l1 (BCL2-like 1) [NCBI Gene 12048]
- **Chemicals:** N,N-Dimethyltryptamine (PubChem CID 6089), DMT (PubChem CID 6089), doxorubicin (PubChem CID 31703)
- **Species:** Rattus norvegicus (taxon 10116), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, Il10 (interleukin 10) [NCBI Gene 25325] {aka IL10X, If2a}, Aif1 (allograft inflammatory factor 1) [NCBI Gene 29427] {aka BART-1, Bart1, iba1, mrf-1}, Ret (ret proto-oncogene) [NCBI Gene 24716], Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, F2 (coagulation factor II, thrombin) [NCBI Gene 29251], Sigmar1 (sigma non-opioid intracellular receptor 1) [NCBI Gene 29336] {aka Oprs1}, Htr2a (5-hydroxytryptamine receptor 2A) [NCBI Gene 29595] {aka 5-HT2A, 5Ht-2}, Hprt1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 24465] {aka Hgprtase, Hprt}, Gdnf (glial cell derived neurotrophic factor) [NCBI Gene 25453] {aka gndf}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, Bdnf (brain-derived neurotrophic factor) [NCBI Gene 24225], Rela (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 309165] {aka NFkB, nos2}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, Gfap (glial fibrillary acidic protein) [NCBI Gene 24387], Syp (synaptophysin) [NCBI Gene 24804] {aka Syp1}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, Cntf (ciliary neurotrophic factor) [NCBI Gene 25707], Gfra1 (GDNF family receptor alpha 1) [NCBI Gene 25454], Bcl2l1 (Bcl2-like 1) [NCBI Gene 24888] {aka Bcl-xl, Bcl2l, Bclx, bcl-X}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 54250] {aka Fgf-2, Fgf2a, bFGF}
- **Diseases:** bleeding (MESH:D006470), atrophy (MESH:D001284), neurotoxic (MESH:D020258), seroma (MESH:D049291), Avulsion (MESH:D000071562), MN degeneration (MESH:D009410), CNS injury (MESH:D002494), neuroinflammation (MESH:D000090862), VRA (MESH:D011843), abnormal gait or mobility (MESH:D014086), tissue damage (MESH:D017695), Astrogliosis (MESH:D005911), corneal desiccation (MESH:D003316), inflammatory (MESH:D007249), necrosis (MESH:D009336), pain (MESH:D010146), nerve damage (MESH:D000080902), injuries (MESH:D014947), hypoxia (MESH:D000860), MN disorders (MESH:D009358), spinal cord injury (MESH:D013119)
- **Chemicals:** tryptamines (MESH:D014363), N, N-dimethyl-ethylamine (MESH:C047305), psilocybin (MESH:D011562), LSD (MESH:D008238), dimethylamine (MESH:C034516), lithium (MESH:D008094), xylene (MESH:D014992), indole (MESH:C030374), CDCl3 (-), toluidine blue (MESH:D014048), formic acid (MESH:C030544), methanol (MESH:D000432), n-hexane (MESH:C026385), nitrogen (MESH:D009584), glutamate (MESH:D018698), Alexa Fluor 488 (MESH:C000711379), water (MESH:D014867), isoflurane (MESH:D007530), alkaloid (MESH:D000470), alcohol (MESH:D000438), xylazine (MESH:D014991), polysulfone (MESH:C017662), ROS (MESH:D017382), DMT (MESH:D004130), riluzole (MESH:D019782), sucrose (MESH:D013395), FAM (MESH:C031179), oxygen (MESH:D010100), glycerol (MESH:D005990), tramadol hydrochloride (MESH:D014147), calcium chloride (MESH:D002122), phosphate (MESH:D010710), 2H (MESH:D003903), dimethyl fumarate (MESH:D000069462), Triton X-100 (MESH:D017830), PFA (MESH:C003043)
- **Species:** Crotalus durissus terrificus (cascabel, subspecies) [taxon 8732], Bubalus bubalis (domestic water buffalo, species) [taxon 89462], Mimosa tenuiflora (species) [taxon 138060], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12856109/full.md

---
Source: https://tomesphere.com/paper/PMC12856109